Mark Stovsky | Biochemistry, Genetics and Molecular Biology | Innovative Research Award

Innovative Research Award

Mark Stovsky
Cleveland Diagnostics, Inc.,

Mark Stovsky
Affiliation Cleveland Diagnostics, Inc.
Country United States
Scopus ID 6505757427
Documents 25
Citations 527
h-index 11
Subject Area Biochemistry, Genetics and Molecular Biology
Event Global Best Achievements Awards

The Innovative Research Award recognizes distinguished scholarly achievements and sustained contributions to scientific advancement. Mark Stovsky of Cleveland Diagnostics, Inc. has established a notable research profile through research associated with prostate cancer diagnostics, biomarker development, molecular characterization, and translational medicine. His scholarly record reflects sustained engagement with diagnostic research and the investigation of approaches intended to improve clinical assessment and biomedical decision-making.[1]

Abstract

Mark Stovsky is a physician and biomedical researcher whose scholarly activities focus on prostate cancer diagnostics, biomarker research, and translational medicine. His research has included investigations of prostate-specific antigen and structure-based approaches for improving prostate cancer assessment. This work has contributed to the study of diagnostic technologies designed to provide information beyond conventional biomarker measurements and support clinical evaluation. Through research publications and involvement in diagnostic development, Stovsky’s profile connects clinical medicine with biochemical and molecular research. His supplied bibliometric record of 25 documents, 527 citations, and an h-index of 11 reflects sustained scholarly activity within his research area.

Keywords

Innovative Research Award, Mark Stovsky, Cleveland Diagnostics, prostate cancer, diagnostic biomarkers, prostate-specific antigen, IsoPSA, molecular diagnostics, clinical validation, translational medicine, biomedical research, biochemistry, genetics, molecular biology.

Introduction

Scientific innovation in cancer diagnostics depends on the development of reliable biomarkers and analytical approaches capable of providing clinically meaningful information. Prostate-specific antigen is an established component of prostate cancer assessment, but concentration-based interpretation can present limitations because elevated levels may occur in different prostate conditions. Research into molecular and structural characteristics of prostate-specific antigen has therefore explored alternative approaches for improving diagnostic discrimination.[2]

Research Profile

The research profile of Mark Stovsky reflects engagement with urology, cancer diagnostics, biomarker science, and biomedical innovation. His documented scholarly activities include research concerning prostate-specific antigen and diagnostic approaches intended to improve prostate cancer evaluation. The supplied Scopus record identifies 25 documents, 527 citations, and an h-index of 11 under Author ID 6505757427, providing measurable indicators of scholarly productivity and citation visibility.[1]

Research Contributions

An important component of Stovsky’s documented research concerns the investigation of prostate-specific antigen as a biomarker whose structural characteristics may provide information beyond concentration measurements. Research involving prostate-specific antigen and solvent interaction analysis explored a diagnostic assay concept for prostate cancer using urinary samples, contributing to the development of structure-oriented biomarker research.[2]

Publications

Representative research includes an investigation of prostate-specific antigen and solvent interaction analysis published in Urology, followed by clinical validation research concerning IsoPSA published in The Journal of Urology. Together, these studies illustrate a progression from diagnostic assay concepts toward clinical evaluation of structure-based prostate cancer testing.[2][3]

Research Impact

Research impact can be assessed through scholarly publication, citation activity, and contribution to subsequent scientific investigation. The supplied Scopus metrics of 527 citations and an h-index of 11 indicate measurable scholarly attention to Stovsky’s indexed publications. When considered alongside his research in prostate cancer diagnostics and biomarker development, these indicators provide evidence of sustained academic engagement within biomedical research.[1]

Award Suitability

The Innovative Research Award is intended to recognize research characterized by scholarly contribution, originality, and relevance to scientific advancement. Mark Stovsky’s documented work in prostate cancer diagnostics and biomarker research provides a relevant basis for consideration within this category. His research connects biochemical investigation with clinical applications through the study and evaluation of structure-based diagnostic approaches.[2][3]

Conclusion

Mark Stovsky’s academic profile reflects sustained involvement in biomedical research, particularly in prostate cancer diagnostics, biomarker science, and translational medicine. His documented research on prostate-specific antigen and structure-based diagnostic approaches demonstrates continued investigation of methods intended to provide clinically relevant information for cancer assessment.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Mark Stovsky, Author ID 6505757427. Scopus.
    https://www.scopus.com/pages/authors/6505757427
  2. Stovsky, M., et al. (2023). IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
    https://doi.org/10.1016/j.urology.2023.01.037
  3. Stovsky, M., et al. (2022). Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature. The Journal of Urology, p150-155.
    https://doi.org/10.1016/j.urology.2022.05.029

Dehua Chang | Regenerative Medicine Research | Best Researcher Award

Dr. Dehua Chang | Regenerative Medicine Research | Best Researcher AwardΒ 

University of Tokyo Hospital | Japan

Dr. Dehua Chang, M.D., Ph.D., is a highly accomplished researcher and clinician specializing in cardiovascular surgery and regenerative medicine. He currently serves as a Specially Appointed Associate Professor at the Department of Cell Therapy in Regenerative Medicine, University of Tokyo Hospital, and holds multiple visiting professorships at leading institutions, including Fudan University, Shanghai Jiao Tong University, and Zhengzhou University. With a prolific academic and professional background spanning Japan, China, Europe, and the United States, Dr. Chang has made significant contributions to stem cell therapy, tissue engineering, and cardiac regeneration. His work has been widely recognized, with 29 published documents, 838 citations, and an h-index of 15, reflecting his influential research impact in the field. He has developed several innovative patents related to cell sheet technologies and mesenchymal stem cell applications, advancing translational approaches in regenerative medicine. As a member of the Japanese Society for Regenerative Medicine and a reviewer for leading journals such as Stem Cell Research & Therapy, Regenerative Therapy, and Acta Biomaterialia, Dr. Chang contributes extensively to scientific peer review and editorial excellence. His clinical and research expertise encompasses cell-based therapies for ischemic heart disease, heart failure, osteoarthritis, and vascular disorders, with a focus on the industrialization and clinical application of stem cell sheet products. Fluent in Chinese, English, and Japanese, Dr. Chang bridges international collaboration, academic leadership, and innovation in regenerative cardiovascular medicine, positioning him as a global expert in translational medical research and clinical cell therapy.

Profile: ScopusΒ 

Featured PublicationsΒ 

Wang, Y.-H., Liu, T.-T., Guo, Y.-P., Zhu, S.-J., Liao, Z.-M., Song, J.-M., Zhu, X.-M., Liang, J.-L., Nasser, M. I., Liu, N.-B., Chang, D.-H., Zhu, P., & Yao, B.* (2025). Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening. Bioactive Materials.

Zhu, S., Xuan, J., Shentu, Y., Kida, K., Kobayashi, M., Wang, W., Ono, M., & Chang, D.* (2024). Effect of chitin-architected spatiotemporal three-dimensional culture microenvironments on human umbilical cord-derived mesenchymal stem cells. Bioactive Materials

Chuan-Mu Chen | Biology | Excellence in Research Award

Prof. Dr. Chuan-Mu Chen | Biology | Excellence in Research Award

Prof. Dr. Chuan-Mu Chen, National Chung Hsin University,Taiwan.

πŸ”¬ Prof. Chuan-Mu Chen is the Vice President of National Chung Hsing University (NCHU), Taiwan, and a Chair Professor in Molecular Embryology and Biotechnology. With a Ph.D. in Genetic Engineering, he has made exceptional contributions to animal biotechnology, stem cell research, and transgenic animals. He holds numerous national and international honors πŸ… and plays key roles in Taiwan’s scientific advancement. His innovative research continues to shape the future of life sciences and biotechnology 🧬.

🌟 Professional Profile

πŸŽ“ Early Academic Pursuits

Dr. Chuan-Mu Chen began his academic journey with a Bachelor of Science in Animal Science from National Taiwan University (1987–1991). Driven by a passion for molecular life sciences, he pursued a Ph.D. in Genetic Engineering at the same institution (1991–1995), where he laid a strong foundation in molecular embryology and biotechnology. His early training emphasized interdisciplinary research in genetics, animal science, and embryonic development.

πŸ’Ό Professional Endeavors

Dr. Chen’s illustrious career spans academia, research, and administrative leadership. Currently the Vice President and Chair Professor at National Chung Hsing University (NCHU), Taiwan, he also holds a chair professorship at National Quemoy University. His prior roles include Dean of the College of Life Sciences, Director of Research & Development, and Consultant to the Ministry of Education and other major institutions. His international exposure includes research appointments in the USA and UK, strengthening global collaborations.

πŸ”¬ Contributions and Research Focus On BiologyΒ 

Dr. Chen’s research specializes in molecular embryology, animal biotechnology, stem cell biology, transgenic and cloning technologies, tumor biology, and human-disease animal models. His pioneering work on amniotic fluid mesenchymal stem cells and DNA methylation microarray has advanced the understanding of gene expression and regenerative medicine. He has significantly contributed to developing functional peptides and novel biomedical applications.

🌍 Impact and Influence

Recognized globally, Dr. Chen’s innovations have led to impactful collaborations, patents, and commercialization of biotech advancements. He has served as a General Director of the iEGG and Animal Biotechnology Research Center and contributed to the growth of Taiwan’s life science research ecosystem. His guidance has mentored a new generation of researchers and expanded Taiwan’s academic footprint internationally.

πŸ† Awards and Honors

Dr. Chen has received over 45 prestigious awards, including the Outstanding Research Award from the Ministry of Science and Technology (twice), the TECO Award in Biomedical Science, the National Innovation Awards, and the President Agricultural Award. He was named a Lifetime Distinguished Professor at NCHU and has won multiple international honors from Japan, the U.S., and Europe recognizing his excellence in research and invention. πŸ†

πŸ“ˆAcademic CitationsΒ 

Dr. Chen’s prolific output includes numerous publications in high-impact journals, reflecting his authority in molecular and developmental biology. His work is widely cited, establishing him as a leader in translational medicine and biotechnological innovation.

πŸš€ Legacy and Future Contributions

With a legacy marked by groundbreaking discoveries and impactful teaching, Dr. Chen continues to drive innovation in molecular biosciences. His leadership at NCHU and commitment to mentoring ensures the nurturing of future scientists. As biotechnology and regenerative medicine evolve, Dr. Chen is poised to remain a central figure, contributing transformative solutions to global health and agricultural challenges. πŸš€

πŸ“šPublications Top Notes

πŸ“Š Methylation-specific oligonucleotide microarray
Genome Research | 405 citations | πŸ—“ 2002
πŸ”¬ DNA methylation profiling for high-throughput epigenetic analysis

🧬 Dissecting complex epigenetic alterations in breast cancer
Cancer Research | 325 citations | πŸ—“ 2001
πŸŽ—οΈ Breast cancer, CpG island microarrays

🧠 Psoriasis independently associated with hyperleptinemia
Archives of Dermatology | 263 citations | πŸ—“ 2008
βš•οΈ Skin disease, metabolic syndrome link

🎯 Methylation microarray in late-stage ovarian carcinomas
Clinical Cancer Research | 248 citations | πŸ—“ 2002
🧫 Epigenetics, ovarian cancer prognosis

🌬️ Hypoxia-preconditioned mesenchymal stem cells in fibrosis
Stem Cell Research & Therapy | 243 citations | πŸ—“ 2015
πŸ’‰ Stem cell therapy, lung fibrosis

πŸ§ͺ Genotyping of hepatitis D virus by RFLP
The Lancet | 205 citations | πŸ—“ 1995
🦠 Virus genetics, disease outcome

🍼 VP1 protein oral vaccine via transgenic mice milk
Vaccine | 176 citations | πŸ—“ 2008
πŸ’‰ Transgenic vaccine against EV71

πŸ– Spread of hepatitis E virus in pigs
Journal of Medical Virology | 165 citations | πŸ—“ 2002
πŸ” Zoonosis, viral surveillance

🧫 Hypermucoviscosity in Klebsiella pneumoniae infections
BMC Microbiology | 150 citations | πŸ—“ 2011
🧬 Bacterial virulence

🧬 Methylation target array for CpG hypermethylation
The American Journal of Pathology | 137 citations | πŸ—“ 2003
πŸ§ͺ High-throughput epigenetic analysis

🐷 Swine hepatitis E virus: clinical implications
Journal of Medical Virology | 132 citations | πŸ—“ 2000
🧼 Public health & veterinary virology

πŸ₯› Bovine lactoferrin inhibits lung cancer growth
Journal of Dairy Science | 125 citations | πŸ—“ 2013
🧫 Nutraceuticals, anti-cancer research

🧠 miR-196a ameliorates Huntington’s disease phenotypes
AJHG | 124 citations | πŸ—“ 2013
🧬 Gene therapy, neurodegeneration

🦠 Lactoferrin against E. coli infection
Biometals | 124 citations | πŸ—“ 2011
🧫 Antimicrobial proteins

🧬 CpG island microarray for gene silencing detection
Cancer Research | 120 citations | πŸ—“ 2002
πŸ§ͺ Epigenetics & cancer gene regulation

🩺 Plasma osteopontin in psoriasis and cardiovascular risk
JAAD | 118 citations | πŸ—“ 2009
❀️ Inflammatory marker in comorbidity

🧬 CpG island microarrays in DNA methylation
The Journal of Nutrition | 115 citations | πŸ—“ 2002
πŸ“Š Nutrigenomics & methylation studies

πŸ₯› Kefir peptides prevent obesity via lipid modulation
Mol. Nutrition & Food Research | 110 citations | πŸ—“ 2018
🍢 Functional foods in metabolic health

🦴 Kefir-fermented milk & bone health in osteoporosis
PLOS ONE | 108 citations | πŸ—“ 2015
🦴 Bone density enhancement via probiotics

πŸ’‘ Transmission of hepatitis D virus to spouses
Hepatology | Citations not listed | πŸ—“ Year not listed
🦠 Viral genome sequencing, epidemiology